ConceptioArchiveClinicalTrials.gov
ClinicalTrials.govpublic full text

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Shanghai YingLi Pharmaceutical Co. Ltd. · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
advanced solid tumor, with a kras g12c mutation, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 885449
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.